** Drug developer Scancell's shares down 27 pct,worst day in nearly three years, after suspends dosing in acancer clinical trial because of quality problems with itsimmunotherapy treatment SCIB1
** Co says current supplies of drug no longer meet originalspecification and are no longer suitable for further use
** The suspension affects 8 patients in a clinical trial, cosays
** Shares at 6-mth lows, with more than 10x their 30-day avgvols gone through in the first half hour of trade (venkateshasoumithri.mamidipudi.thomsonreuters.com@reuters.net)